tiprankstipranks
Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
US Market
MAZE
Maze Therapeutics, Inc.
RESEARCH TOOLSreports
Want to see MAZE full AI Analyst Report?

Maze Therapeutics, Inc. (MAZE) Stock Forecast & Price Target

93 Followers
See the Price Targets and Ratings of:

MAZE Analyst Ratings

Strong Buy
12Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Maze
Therapeutics, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MAZE Stock 12 Month Forecast

Average Price Target

$64.45
▲(129.46% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Maze Therapeutics, Inc. in the last 3 months. The average price target is $64.45 with a high forecast of $110.00 and a low forecast of $46.00. The average price target represents a 129.46% change from the last price of $28.09.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","111":"$111","33.75":"$33.8","59.5":"$59.5","85.25":"$85.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":64.45454545454545,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$64.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$46.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,33.75,59.5,85.25,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.05,35.276923076923076,41.503846153846155,47.730769230769226,53.95769230769231,60.184615384615384,66.41153846153846,72.63846153846154,78.86538461538461,85.0923076923077,91.31923076923077,97.54615384615384,103.77307692307691,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.05,31.773426573426576,34.49685314685315,37.22027972027972,39.9437062937063,42.66713286713287,45.39055944055944,48.11398601398602,50.83741258741259,53.560839160839166,56.28426573426574,59.00769230769231,61.73111888111889,{"y":64.45454545454545,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.05,30.353846153846156,31.657692307692308,32.96153846153846,34.26538461538462,35.56923076923077,36.87307692307692,38.176923076923075,39.48076923076923,40.784615384615385,42.08846153846154,43.392307692307696,44.69615384615385,{"y":46,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.9,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.43,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.53,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.61,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.05,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$110.00Average Price Target$64.45Lowest Price Target$46.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on MAZE
Danielle Brill
Truist Financial
Truist Financial
$68→$64
Buy
127.84%
Upside
Assigned
04/14/26
Maze Therapeutics price target lowered to $64 from $68 at TruistMaze Therapeutics price target lowered to $64 from $68 at Truist
H.C. Wainwright Analyst forecast on MAZE
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
$110
Buy
291.60%
Upside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Immuneering (NASDAQ: IMRX) and Maze Therapeutics, Inc. (NASDAQ: MAZE)
J.P. Morgan Analyst forecast on MAZE
Anupam Rama
J.P. Morgan
J.P. Morgan
$52→$58
Buy
106.48%
Upside
Assigned
03/31/26
J.P. Morgan Sticks to Its Buy Rating for Maze Therapeutics, Inc. (MAZE)
Mizuho Securities Analyst forecast on MAZE
Salim Syed
Mizuho Securities
Mizuho Securities
$97
Buy
245.32%
Upside
Reiterated
03/30/26
Maze Therapeutics, Inc. (MAZE) Gets a Buy from Mizuho Securities
LifeSci Capital Analyst forecast on MAZE
Rami Katkhuda
LifeSci Capital
LifeSci Capital
$57
Buy
102.92%
Upside
Reiterated
03/28/26
Maze Therapeutics, Inc. (MAZE) Gets a Buy from LifeSci Capital
TD Cowen Analyst forecast on MAZE
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
03/26/26
Analysts Conflicted on These Healthcare Names: Maze Therapeutics, Inc. (NASDAQ: MAZE), Azitra Inc (NYSE MKT: AZTR) and Arrowhead Pharmaceuticals (NASDAQ: ARWR)
Wedbush Analyst forecast on MAZE
Laura Chico
Wedbush
Wedbush
$58
Buy
106.48%
Upside
Reiterated
03/26/26
Wedbush Reaffirms Their Buy Rating on Maze Therapeutics, Inc. (MAZE)
Wells Fargo Analyst forecast on MAZE
Sadia Rahman
Wells Fargo
Wells Fargo
$55
Buy
95.80%
Upside
Reiterated
03/26/26
Analysts Offer Insights on Healthcare Companies: Celcuity (NASDAQ: CELC) and Maze Therapeutics, Inc. (NASDAQ: MAZE)
BTIG Analyst forecast on MAZE
Julian Harrison
BTIG
BTIG
$46
Buy
63.76%
Upside
Reiterated
03/25/26
Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829
Leerink Partners Analyst forecast on MAZE
Joseph Schwartz
Leerink Partners
Leerink Partners
$50
Buy
78.00%
Upside
Reiterated
03/25/26
Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Biomea Fusion (BMEA)
Raymond James Analyst forecast on MAZE
Martin Auster
Raymond James
Raymond James
$56
Buy
99.36%
Upside
Reiterated
03/25/26
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (NASDAQ: BMEA) and Maze Therapeutics, Inc. (NASDAQ: MAZE)
Guggenheim Analyst forecast on MAZE
Debjit Chattopadhyay
Guggenheim
Guggenheim
$46→$58
Buy
106.48%
Upside
Assigned
03/04/26
Maze Therapeutics price target raised to $58 from $46 at GuggenheimMaze Therapeutics price target raised to $58 from $46 at Guggenheim
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on MAZE
Danielle Brill
Truist Financial
Truist Financial
$68→$64
Buy
127.84%
Upside
Assigned
04/14/26
Maze Therapeutics price target lowered to $64 from $68 at TruistMaze Therapeutics price target lowered to $64 from $68 at Truist
H.C. Wainwright Analyst forecast on MAZE
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
$110
Buy
291.60%
Upside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Immuneering (NASDAQ: IMRX) and Maze Therapeutics, Inc. (NASDAQ: MAZE)
J.P. Morgan Analyst forecast on MAZE
Anupam Rama
J.P. Morgan
J.P. Morgan
$52→$58
Buy
106.48%
Upside
Assigned
03/31/26
J.P. Morgan Sticks to Its Buy Rating for Maze Therapeutics, Inc. (MAZE)
Mizuho Securities Analyst forecast on MAZE
Salim Syed
Mizuho Securities
Mizuho Securities
$97
Buy
245.32%
Upside
Reiterated
03/30/26
Maze Therapeutics, Inc. (MAZE) Gets a Buy from Mizuho Securities
LifeSci Capital Analyst forecast on MAZE
Rami Katkhuda
LifeSci Capital
LifeSci Capital
$57
Buy
102.92%
Upside
Reiterated
03/28/26
Maze Therapeutics, Inc. (MAZE) Gets a Buy from LifeSci Capital
TD Cowen Analyst forecast on MAZE
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
03/26/26
Analysts Conflicted on These Healthcare Names: Maze Therapeutics, Inc. (NASDAQ: MAZE), Azitra Inc (NYSE MKT: AZTR) and Arrowhead Pharmaceuticals (NASDAQ: ARWR)
Wedbush Analyst forecast on MAZE
Laura Chico
Wedbush
Wedbush
$58
Buy
106.48%
Upside
Reiterated
03/26/26
Wedbush Reaffirms Their Buy Rating on Maze Therapeutics, Inc. (MAZE)
Wells Fargo Analyst forecast on MAZE
Sadia Rahman
Wells Fargo
Wells Fargo
$55
Buy
95.80%
Upside
Reiterated
03/26/26
Analysts Offer Insights on Healthcare Companies: Celcuity (NASDAQ: CELC) and Maze Therapeutics, Inc. (NASDAQ: MAZE)
BTIG Analyst forecast on MAZE
Julian Harrison
BTIG
BTIG
$46
Buy
63.76%
Upside
Reiterated
03/25/26
Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829
Leerink Partners Analyst forecast on MAZE
Joseph Schwartz
Leerink Partners
Leerink Partners
$50
Buy
78.00%
Upside
Reiterated
03/25/26
Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Biomea Fusion (BMEA)
Raymond James Analyst forecast on MAZE
Martin Auster
Raymond James
Raymond James
$56
Buy
99.36%
Upside
Reiterated
03/25/26
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (NASDAQ: BMEA) and Maze Therapeutics, Inc. (NASDAQ: MAZE)
Guggenheim Analyst forecast on MAZE
Debjit Chattopadhyay
Guggenheim
Guggenheim
$46→$58
Buy
106.48%
Upside
Assigned
03/04/26
Maze Therapeutics price target raised to $58 from $46 at GuggenheimMaze Therapeutics price target raised to $58 from $46 at Guggenheim
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Maze Therapeutics, Inc.

3 Months
xxx
Success Rate
5/7 ratings generated profit
71%
Average Return
+44.94%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +44.94% per trade.
1 Year
Joseph SchwartzLeerink Partners
Success Rate
6/7 ratings generated profit
86%
Average Return
+133.74%
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +133.74% per trade.
2 Years
xxx
Success Rate
6/7 ratings generated profit
86%
Average Return
+105.59%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +105.59% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MAZE Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
3
2
0
11
14
Buy
7
10
12
18
14
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
12
12
29
28
In the current month, MAZE has received 28 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MAZE average Analyst price target in the past 3 months is 64.45.
Each month's total comprises the sum of three months' worth of ratings.

MAZE Financial Forecast

MAZE Earnings Forecast

Next quarter’s earnings estimate for MAZE is -$0.57 with a range of -$0.91 to -$0.32. The previous quarter’s EPS was -$0.65. MAZE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MAZE has Performed in-line its overall industry.
Next quarter’s earnings estimate for MAZE is -$0.57 with a range of -$0.91 to -$0.32. The previous quarter’s EPS was -$0.65. MAZE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MAZE has Performed in-line its overall industry.
No data currently available

MAZE Sales Forecast

Next quarter’s sales forecast for MAZE is $10.63M with a range of $0.00 to $20.00M. The previous quarter’s sales results were $0.00. MAZE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MAZE has Performed in-line its overall industry.
Next quarter’s sales forecast for MAZE is $10.63M with a range of $0.00 to $20.00M. The previous quarter’s sales results were $0.00. MAZE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MAZE has Performed in-line its overall industry.

MAZE Stock Forecast FAQ

What is MAZE’s average 12-month price target, according to analysts?
Based on analyst ratings, Maze Therapeutics, Inc.’s 12-month average price target is 64.45.
    What is MAZE’s upside potential, based on the analysts’ average price target?
    Maze Therapeutics, Inc. has 129.46% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MAZE a Buy, Sell or Hold?
          Maze Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Maze Therapeutics, Inc.’s price target?
            The average price target for Maze Therapeutics, Inc. is 64.45. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $110.00 ,the lowest forecast is $46.00. The average price target represents 129.46% Increase from the current price of $28.09.
              What do analysts say about Maze Therapeutics, Inc.?
              Maze Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of MAZE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.